Utah Medical Products, Inc.
NASDAQ:UTMD · NASDAQ Global Select
+$1.10 today
Vol 0.02M · Avg 0.01M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:UTMD · Revenue to Net Income
Key Ratios
Analysis
$37.5M of revenue converted into $10.8M of net income for the selected period. Gross margin is 53.8% and net margin is 28.9%, showing how much revenue survives after costs and taxes. EPS is $3.38, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.5M -5.8% | $40.9M -18.6% | $50.2M -3.9% | $52.3M +6.6% | $49.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $18.6M +11.2% | $16.8M -17.0% | $20.2M +0.5% | $20.1M +10.7% | $18.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $19.9M -17.7% | $24.1M -19.6% | $30.0M -6.7% | $32.2M +4.1% | $30.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 51.6% -7.4pp | 59.0% -0.8pp | 59.8% -1.8pp | 61.6% -1.4pp | 63.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $668.0K -17.8% | $813.0K +45.2% | $560.0K +13.6% | $493.0K -6.3% | $526.0K | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $7.8M +40.2% | $5.6M -56.2% | $12.7M +6.6% | $11.9M +3.5% | $11.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $8.5M -19.7% | $10.5M -20.5% | $13.3M +6.9% | $12.4M +3.1% | $12.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $3.0M +6.5% | $2.8M -56.5% | $6.4M -10.1% | $7.1M -2.8% | $7.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $17.1M -12.8% | $19.6M -20.9% | $24.8M -10.8% | $27.7M +5.3% | $26.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 44.3% -3.6pp | 47.9% -1.4pp | 49.3% -3.8pp | 53.1% -0.6pp | 53.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $11.4M -16.1% | $13.6M -19.0% | $16.8M -15.2% | $19.8M +4.8% | $18.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 29.6% -3.6pp | 33.2% -0.2pp | 33.4% -4.4pp | 37.9% -0.6pp | 38.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $3.4M | $0 -100.0% | $661.0K +298.2% | $166.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.7M -15.6% | $3.2M -3.1% | $3.3M +281.1% | $869.0K +380.1% | $181.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $14.1M -16.0% | $16.8M -16.4% | $20.1M -2.8% | $20.7M +8.4% | $19.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 36.6% -4.4pp | 41.1% +1.1pp | 40.0% +0.5pp | 39.5% +0.7pp | 38.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.8M -3.6% | $2.9M -15.2% | $3.5M -17.5% | $4.2M -2.0% | $4.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $11.3M -18.7% | $13.9M -16.6% | $16.6M +1.0% | $16.5M +11.4% | $14.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 29.3% -4.6pp | 33.9% +0.8pp | 33.1% +1.6pp | 31.5% +1.4pp | 30.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 -13.9% | $4 -13.3% | $5 +0.9% | $5 +11.9% | $4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 -12.1% | $4 -13.3% | $5 +1.1% | $5 +11.9% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $3.3M -5.5% | $3.5M -3.7% | $3.6M -0.0% | $3.6M -0.3% | $3.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $3.2M -7.5% | $3.5M -3.7% | $3.6M -0.2% | $3.6M -0.5% | $3.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Prenetics Global Limited
NASDAQ:PRE
$343.75M
OraSure Technologies, Inc.
NASDAQ:OSUR
$298.46M
Perspective Therapeutics, Inc.
AMEX:CATX
$232.14M
Profound Medical Corp.
NASDAQ:PROF
$205.76M
InfuSystem Holdings, Inc.
AMEX:INFU
$183.45M
KORU Medical Systems, Inc.
NASDAQ:KRMD
$180.75M
Coherus Oncology, Inc.
NASDAQ:CHRS
$173.45M
Protalix BioTherapeutics, Inc.
AMEX:PLX
$169.60M
Neuronetics, Inc.
NASDAQ:STIM
$85.21M
Nyxoah S.A.
NASDAQ:NYXH
$60.36M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does UTMD generate?
Utah Medical Products, Inc. (UTMD) reported $38.52M of revenue in fiscal 2025.
Is UTMD profitable?
Utah Medical Products, Inc. (UTMD) reported $11.29M of net income, with a net margin of 29.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.